Pharmaceuticals

Hypera S.A.

Hypera S.A. released FY2026 Q1 earnings on April 28 After-Market (EST), actual revenue USD 384.62 M (forecast USD 377.71 M), actual EPS USD 0.1051

Hypera S.A. to Release FY2026 Q1 Earnings on April 28 After-Market EST, Forecast Revenue USD 396.86 M

Hypera S.A. released FY2025 Q4 earnings on March 12 After-Market (EST), actual revenue USD 408.45 M (forecast USD 403.84 M), actual EPS USD 0.13

Hypera S.A. released FY2025 earnings on March 12 After-Market EST, actual revenue USD 1.401 B (forecast USD 1.406 B), actual EPS USD 0.3418

Hypera S.A. to Release FY2025 Earnings on March 12 After-Market EST, Forecast Revenue USD 1.476 B

Hypera S.A. released FY2025 9-month earnings on October 28 After-Market EST, actual revenue USD 999.11 M, actual EPS USD 0.2187

Hypera S.A. released FY2025 Q3 earnings on October 28 After-Market (EST), actual revenue USD 418.64 M (forecast USD 418.07 M), actual EPS USD 0.1351

Hypera S.A. to Release FY2025 Q3 Earnings on October 28, 2025 (EST), Forecast Revenue USD 407.18 M

Hypera S.A. released FY2025 Semi-Annual earnings on August 6 After-Market EST, actual revenue USD 575.74 M, actual EPS USD 0.0801

Hypera S.A. released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 392.86 M (forecast USD 393.21 M), actual EPS USD 0.122

Hypera S.A. to Release FY2025 Q2 Earnings on August 6, 2025 (EST), Forecast Revenue USD 389.01 M

Hypera S.A. released FY2025 Q1 earnings on April 23 After-Market EST, actual revenue USD 187.61 M (forecast USD 179.88 M), actual EPS USD -0.0384

Hypera S.A. to Release FY2025 Q1 Earnings on April 23 Pre-Market EST, Forecast Revenue USD 176.42 M

Hypera S.A. released FY2024 annual earnings on March 20 After-Market (EST), actual revenue USD 1.347 B (forecast USD 1.331 B), actual EPS USD 0.3803

Hypera S.A. released FY2024 Q4 earnings on March 20 After-Market EST, actual revenue USD 244.55 M (forecast USD 262.39 M), actual EPS USD 0.0212

Hypera S.A. to Release FY2024 Earnings on March 20 After-Market EST, Forecasted Revenue 1.309 B USD

Hypera S.A. released FY2024 Q3 earnings on November 13 After-Market (EST), actual revenue 352.47 MUSD (forecast 350.4 MUSD), actual EPS 0.1088 USD

Hypera S.A. released FY2024 Cumulative 3Q Earnings on November 13 (EST), with actual revenue of 1.108 B USD and EPS of 0.3697

Hypera S.A. to Release FY2024 Q3 Earnings on November 13 After-Market EST, Forecast Revenue 350.4 M USD

Akanda

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Agape ATP

Co-Diagnostics

Netcapital

Tradr 2X Long QBTS Daily ETF

NewGenIvf

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

Liminatus Pharma

HYPMY

Citi analyst has given Hypera S.A. (HYPE3) a Buy rating with a price target of BRL28.00. The current analyst consensus is a Moderate Buy with an average target of BRL31.50, indicating a 34.79% upside. Scotiabank also maintains a Buy rating with a target of BRL35.00.

Tip Ranks

Citigroup

Bank of Nova Scottia

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Positive Report for Hypera S.A. (HYPE3) from Citi

BRAZ

Scotiabank analyst Felipe Ucros has reaffirmed a Buy rating for Hypera S.A. (HYPE3) with a price target of BRL35.00. Ucros, a 3-star analyst with a 5.1% average return and a 64.71% success rate, aligns with the Moderate Buy consensus rating for the stock, which also has an average price target of BRL35.00 according to TipRanks.

Global X Brazil Active ETF

Scotiabank Sticks to Its Buy Rating for Hypera S.A. (HYPE3)

Hypermarcas (OTCMKTS:HYPMY) experienced a significant decline in short interest in April, dropping 99.5% to just 16 shares as of April 15th. This is down from 3,024 shares on March 31st, with approximately 0.0% of shares short sold. The stock traded down to $4.43, with a market cap of $3.12 billion and a PE ratio of 13.03. The company reported $0.13 EPS for the last quarter, with revenue of $414.22 million and a net margin of 15.71%.

Market Beat

Hypermarcas (OTCMKTS:HYPMY) Short Interest Down 99.5% in April

Hypermarcas (OTCMKTS:HYPMY) experienced a significant drop in short interest, falling 100% from 50,686 shares on January 29 to just 16 shares by February 13. Currently, only 0.0% of the company's shares are sold short, with a days-to-cover ratio of 0.0 days based on an average daily volume of 90,351 shares. The stock traded at $4.50, with a market cap of $2.85 billion and a P/E ratio of 19.57. Hypermarcas is a Brazilian consumer health and pharmaceutical company.

ISHRS L Amer 40

Short Interest in Hypermarcas (OTCMKTS:HYPMY) Drops By 100.0%

Hypera S.A.(HYPMY.US)

Positive Report for Hypera S.A. (HYPE3) from Citi

Scotiabank Sticks to Its Buy Rating for Hypera S.A. (HYPE3)

Hypermarcas (OTCMKTS:HYPMY) Short Interest Down 99.5% in April

Short Interest in Hypermarcas (OTCMKTS:HYPMY) Drops By 100.0%